Lexavon (Levofloxacin Hemihydrate)

Levofloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By inhibiting these targets, the drug stops bacterial cell division, leading to bacterial death. This bactericidal action reduces the infection load on the ocular surface.

The dosing regimen for Lexavon is determined by the prescribing clinician based on the specific infection, severity and patient factors. The prescriber will specify the number of drops, frequency and duration of therapy on the prescription label.

Safety of levofloxacin ophthalmic use in pregnancy or while breastfeeding has not been established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Lexavon, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lexavon (levofloxacin) belongs to the fluoroquinolone class, offering broad‑spectrum coverage against Gram‑negative and Gram‑positive ocular pathogens. Compared with older agents such as ciprofloxacin, levofloxacin often provides higher potency with once‑daily dosing options, though choice depends on local resistance patterns and physician preference.

Lexavon should be stored at room temperature, below 25 °C, in its original container. Keep the bottle tightly closed, protect it from direct sunlight and moisture, and discard any solution that appears discolored or cloudy.

Lexavon is applied as eye drops. The prescribed number of drops is placed into the conjunctival sac of the affected eye(s) at the intervals indicated by the prescriber, typically without touching the tip of the bottle to the eye or surrounding tissues.

Serious risks, although rare, include severe allergic reactions such as Stevens‑Johnson syndrome, corneal ulceration, significant vision loss and systemic hypersensitivity reactions. Patients should seek immediate medical attention if they experience worsening eye pain, swelling, rash or any signs of an allergic response.

Lexavon should not be used by individuals with a known hypersensitivity to levofloxacin, other fluoroquinolones, or any component of the formulation. It is also contraindicated in patients where the risk of tendon rupture or severe systemic fluoroquinolone effects outweighs the therapeutic benefit.